US Merck
CompanyUnited States
US Merck develops one asset, approved (Welireg in renal cell carcinoma). Mostly small molecule acting on EPAS1; based in the United States.
- 1
- Asset
- Furthest stage
- Approved
- 0
- Trials
- 0
- Signals
Pipeline
1Inhibits hypoxia-inducible factor 2 alpha, suppressing hypoxia-responsive gene expression supporting tumor growth.
Approved, Small molecule, EPAS1, renal cell carcinoma
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Similar companies6